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ADD cut-point was based on the ineffectiveness of DF in reducing the number of 
new brain lesions at doses < 360 mg/day.1 Results: The study sample consisted of 
2,879 patients; 19.8% relapsed within 9 months, with an average time to relapse of 
110 days (standard deviation: 77.9). A higher proportion of non-adherent patients 
relapsed versus adherent patients (23.4% vs. 17.9%; p= 0.0004). A higher propor-
tion of patients with suboptimal ADD experienced relapse compared with those 
with ADD ≥ 360 mg/day (26.7% vs. 17.9%, p< 0.0001). Non-persistence was associ-
ated with a higher occurrence of relapse compared with persistence (25.0% vs. 
18.2%, p= 0.0001). ConClusions: Non-adherence and suboptimal dosing with DF 
were related to higher relapse rates in MS patients in a real-world setting. Further 
research is needed to confirm these findings for other DMTs and to quantify the 
level of non-adherence with its impact on effectiveness.REFERENCES: 1. Kappos 
L, et al. Lancet. 2008;372:1463-72. 2. Chastek BJ, et al. J Med Econ. 2010;13:618-25.
ReFeRenCes:
1. Kappos L, et al. Lancet. 2008;372:1463-72.
2. Chastek BJ, et al. J Med Econ. 2010;13:618-25.
PND90
INequalItIes IN access to treatmeNt for multIPle sclerosIs IN 
eNglaND coNtINue DesPIte servIce ImProvemeNt INItIatIves aND 
PolIcy reforms
Hickey D, Leatham O, Macaulay R
PAREXEL, London, UK
objeCtives: Multiple sclerosis (MS) is an acquired chronic immune-mediated 
inflammatory condition of the central nervous system. It is the commonest cause 
of serious physical disability in adults of working age. Inequalities in access to 
treatment and care for MS have been recognised within the UK and when the UK 
is compared with Europe eg. 69% of patients in Germany have access to disease 
modifying therapies versus 21% of patients in the UK. Recent NICE guidance has 
been issued to tackle the inequalities in access to care for MS in England, however 
uptake of NICE Guidance is not uniform across the country, leading to delays and 
restrictions in access to treatment for patients in some areas. This paper aims to 
assess the current variation in access to treatment for MS in England. Methods: 
Prescribing of fingolimod for MS in England was examined using the NHS England 
Innovation Scorecard for Key Secondary Care Medicines per 100,000 population. 
Uptake of fingolimod across the 25 area teams was examined. Results: Despite 
positive NICE guidance for fingolimod issued in April 2012 there are major differ-
ences in the uptake of fingolimod in England. The highest uptake can be seen in 
the London area and in other area team geographies in the south. Uptake in these 
areas is at least 3 fold and in some cases 7 fold greater than that seen in area team 
geographies in the North West. Some of this variation may be explained by proximity 
to specialist care centres, however the existence of these centres does not explain 
the extent of the variation. ConClusions: Variations in access to treatment for 
MS in England persist despite NICE guidance and NHS reform aimed at addressing 
these inequalities.
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objeCtives: Multiple Sclerosis (MS) is a progressive and debilitating condition with 
long-term impacts on patients and healthcare resources. Natalizumab is a disease-
modifying biologic used in MS and administered by intravenous infusion every 28 
days. This analysis evaluated the impact of natalizumab on hospital activity using 
Hospital Episodes Statistics (HES) data. Methods: A retrospective analysis of HES 
was performed using data for the specific period January 2010 to May 2012 (29 
consecutive months). Data after May 2012 was not used due to the introduction of 
a second drug which could not be differentiated from natalizumab. A systematic 
HES coding search identified patients via ICD and OPCS codes and patterns of hos-
pital attendance. Attendances were collated for the period from 6 months pre- and 
6 months post- natalizumab initiation. Healthcare utilisation metrics included: 
number of planned & unplanned hospital visits, planned & unplanned bed days, 
and outpatient appointments. Results: Comparing pre- with post- natalizumab 
periods there was a 50.0% reduction in mean unplanned hospital visits per patient (p 
= 0.010) and a 49.6% reduction in the mean number of bed days per unplanned visit 
(p = 0.027). Other observations included a 74.8% reduction in the mean number of 
unplanned bed days per patient (p = 0.138) and a 44.8% increase in mean outpatient 
appointments per patient (p = 0.351) however these were not statistically significant. 
As expected, natalizumab was associated with an increase in planned admissions 
although the mean number of bed days per planned admission was reduced by 
87.0% (p = 0.004). The changes to in-patient admissions were estimated to deliver a 
small reduction in healthcare expenditure. ConClusions: The pattern of changes 
in hospital activity associated with natalizumab support the expected positive clini-
cal outcomes. Confounding aspects were an identification bias in the non-random 
sampling and the potential for a regression to the mean effect.
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objeCtives: There is currently no cure for Duchenne muscular dystrophy (DMD), 
which results in progressive paralysis and death generally in early adulthood. 
Available treatments only address symptoms, with limited success. However, sev-
eral new therapies targeting underlying genetic components of the disease have 
passed pre-clinical phases of drug development. In anticipation of new therapies 
coming to market, we sought to examine current treatment patterns, resource 
1b, Peginterferon beta-1a, Teriflunomide, Dimethyl Fumarate and Azathioprine, 
detected by ATC Code. We extrapolated results to whole SHI by adjusting for dif-
ferences in demographics of insured between TK and SHI. Results: G-BA issued 
additional benefit of Fingolimod only for patients with rapidly evolving severe RRMS, 
i.e. 1.500 patients in Germany. We observed 9.538 patients with MS and prescrip-
tion of Fingolimod in SHI in 2013 and 11.085 in 2014, corresponding to about every 
10th patient with MS and prescription of DMT. Total outpatient pharmaceutical 
expenditure for DMT was million € 1,843 in 2014, million € 210 (11.4%) caused by 
Fingolimod. ConClusions: HTA and drug safety warnings don´t seem to influence 
prescribing behaviour. This might be accompanied by additional costs for SHI and 
doubtful benefit for patients. Whether marketing or patient demand is responsible 
for over-prescription needs to be discussed elsewhere.
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objeCtives: Fingolimod oral capsules were the first oral disease modifying agent 
(DMT) approved in the United States (US) in September 2010 for the treatment of 
relapsing remitting multiple sclerosis (RRMS). The objective of this study is to assess 
the characteristics of RRMS patients taking Fingolimod capsules in the US. Methods: 
A large US administrative retrospective claims database was used to identify patients 
diagnosed with RRMS and were prescribed Fingolimod between January 2010 to 
December 2012 were included in the study. All patients were ≥ 18 years of age and 
continuously enrolled in the same health plan for a year. Descriptive statistics and 
chi-square tests were performed on the data and statistical significance level was 
set a priori at 0.05. Results: There were a total of 28,447 patients that met the study 
inclusion criteria. Of these, 21,629 (75.9%) were females, mean age was 49.1±10.0 
years, and males were older than females (49.78 vs 48.9 years; P< 0.001) with a sta-
tistical significance different between them. Thirty four percentage of the patients 
were from Midwest, 25.5% were from East, 34.4% from south and 5.2% from West of 
the USA. Thirty three percentage of the patient’s prescription was with their health 
plan formulary and received an average of supply of 31.6 ± 13.6 days. Majority (60.9%) 
of the patients was under group coverage and 59.1% of patients were diagnosed 
with having mental health problems. Females enrolled continuously (5.1 ± 2.4 vs 
5.0 ± 2.4 years) much longer than males in the same health plan. But, females had a 
higher number of total claims (488.2 ± 389.0 vs 416.6 ± 389.0) during the enrollment 
period. ConClusions: Majority of the patients taking Fingolimod was females and 
had more number of claims related to MS than males. And, majority of the patients 
were dispensed Fingolimod for only one month supply.
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objeCtives: The objective of this study is to assess the characteristics of relapsing 
remitting multiple sclerosis patients taking disease modifying therapies (DMTs) in 
the US. Methods: A large US administrative retrospective claims database was 
used to identify patients diagnosed with Multiple Sclerosis (MS) and were pre-
scribed DMTs between January 2010 to December 2012 were included in the study. 
All patients were ≥ 18 years of age and continuously enrolled in the same health 
plan for a year. Descriptive statistics and chi-square tests were performed on the 
data and statistical significance level was set a priori at 0.05. Results: There were 
a total of 741,065 patients that met the study inclusion criteria. The mean age of the 
patients was 52.38 ± 10.50 years, 75.7% of the patients were females, and majority 
of the patients were between 41 to 64 years of age (73.5%). Thirty two percent of 
the patients were from East, 34.6% were from Midwest, 25% from South and 7.8% is 
from West region. 56.6% of the patients were on a group coverage plan and 62.6% of 
the patients were on a DMT prescription that is under their health plan formulary. 
Majority of the patients (92.9%) were prescribed 30 days’ supply of DMTs, 6.3% 
were on 90 days’ supply and only 0.8% were on 60 days’ supply of DMTs. More 
than half of the patients (55.7%) were diagnosed with mental health problems in 
addition to their RRMS as a primary diagnosis. On average, patients were continu-
ously enrolled for 5.36 ± 2.40 years and submitting around 446 claims during this 
period. ConClusions: The majority of the patients was females and was between 
41 to 64 years of age. And majority of the patients received 30 days’ supply of DMTs.
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objeCtives: To explore the relationship between medication-use patterns of mul-
tiple sclerosis (MS) disease-modifying therapy (DMT) and relapse in a real-world 
setting. Methods: This was a retrospective, observational study using administra-
tive claims data. Dimethyl fumarate (DF), a DMT, was selected for analysis due to 
availability of medication-dosing data in relation to efficacy observed in a clinical 
trial.1 Adult MS patients with DF claims (March 2013–January 2014) continuously 
enrolled for 9 months before and after therapy initiation were included. A validated 
algorithm was used to define relapse by either an inpatient claim with a primary 
MS diagnosis or a systemic corticosteroid claim within 7 days of an MS outpa-
tient visit.2 Medication-use patterns were assessed by non-adherence (medica-
tion possession ratio (MPR) < 0.90), suboptimal average daily dose (ADD < 360 mg/
day), and treatment non-persistence (DMT switch or ≥ 30-day gap in therapy). The 
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objeCtives: The aim of this research is to assess the humanistic and economic 
burden of focal drug-refractory epilepsy in Europe. Methods: A PubMed litera-
ture review was performed to identify publications from January 2004 to December 
2014 on prevalence and incidence, impact on quality of life and associated costs of 
epilepsy. Results: In Europe around 6 million people have epilepsy, with 30-45% 
of patients being drug-refractory and 70% of those having focal drug-refractory 
epilepsy. The prevalence and incidence rate of epilepsy is 457 and 43.87 per 100.000 
persons, respectively. Epilepsy is associated with psychiatric comorbidities, chronic 
somatic conditions, significantly lower quality of life and 2-11 times higher all-cause 
mortality than the general population. In 2004 health care expenditures for the 
treatment of epilepsy accounted for 0.2% of the total European national income 
and the annual cost per patient varied from € 2.000 to € 11.500. In 2010, the yearly 
cost of epilepsy ranged from € 13.8 to € 20 billion. The cost of epilepsy depends on the 
severity and frequency of seizures and if patients are drug-refractory (20% to 40% 
of drug-refractory patients account for 80% of the costs). The main cost drivers of 
epilepsy treatment are hospitalizations, antiepileptic drug costs and indirect costs 
(due to high unemployment rate; 46% compared with 19% for the matched control 
population). Standard therapy for drug-refractory focal epilepsy is open surgery 
which is highly effective but also highly invasive and requires strict screening cri-
teria. Minimally invasive surgical techniques are an alternative to open surgery and 
have shown promising clinical benefits with lower neurological impairment and less 
hospital stays compared with open surgery. ConClusions: This data highlights the 
high humanistic and economic burden of focal drug-refractory epilepsy in Europe, 
and the need for new procedures to improve health outcomes and reduce health 
care resource utilization.
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objeCtives: In recent years, health technology assessment (HTA) agencies have 
encountered substantial technical challenges in assessing the relative value of new 
therapies for multiple sclerosis (MS), potentially delaying patient access to promis-
ing drugs. We assessed the impact of contrasting approaches to HTA in Germany and 
the UK on patient access to new therapies for MS. Methods: Technology apprais-
als performed by the National Institute for Health and Care Excellence (NICE) and 
Institute for Quality and Efficiency in Healthcare (IQWiG) since the Pharmaceuticals 
Market Reorganisation Act (AMNOG) in January 2011 were assessed. Quantitative 
and qualitative assessment of appraisal decisions in the context of overall assess-
ment processes, evidence requirements and anticipated patient impact were con-
ducted for each technology. Results: Three therapies have been assessed by both 
NICE and IQWiG (fingolimod, dimethyl fumarate and teriflunomide); both bodies 
have assessed additional therapies independently. All three technologies were rec-
ommended by NICE in restricted patient populations, with an agreed price discount. 
NICE faced considerable technical methodological challenges during the assess-
ment process, including comparator selection (blended versus pair-wise incremen-
tal analyses), assessment versus non-cost-effective beta-interferon comparators 
and appropriate use of mixed treatment comparisons. In some cases, modelling 
assumptions accepted in previous appraisals were criticised by NICE in subsequent 
submissions. By contrast, IQWiG and the Federal Joint Committee (G-BA) concluded 
that all drugs provided no proven clinical benefit, except fingolimod (minor benefit 
in limited subset of patients with rapidly-evolving severe relapsing-remitting MS), 
due to limited clinical data versus IQWiG-specified comparators. ConClusions: 
Patients in Germany can access all three therapies, consistent with their market-
ing authorisations, despite the negative IQWiG appraisal recommendations. In the 
UK, however, fewer patient subgroups can access the same therapies, partly due to 
evolving methodologies used by NICE to assess cost-effectiveness. Greater under-
standing of challenges that impact HTA decisions may facilitate earlier patient 
access to promising MS therapies.
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objeCtives: The primary objective of this analysis was to model the clinical and 
cost effectiveness of glatiramer acetate (GA) using 6-year data from the UK Multiple 
Sclerosis Risk Sharing Scheme (RSS). Methods: A continuous Markov model was 
developed to assess mean Expanded Disability Status Scale (EDSS) and utility at 
year-6 and to determine whether this was consistent with a cost-effective target of 
£36,000 per quality-adjusted life year (QALY) projected over 20 years. In populating 
the model, data from patients fulfilling the Association of British Neurologists (ABN) 
2001 guidelines were analysed together with matched patient data from the British 
Columbia Multiple Sclerosis database (BCMS) as a comparator. Primary outcome 
was the progression ratio, measured both as EDSS score and utility, determined for 
the GA treated group by adjusting within the model the theoretical ratio imposed 
on the comparator patients until the difference between the theoretical and actual 
treated groups was mathematically zero. This effective ratio was input into the cost-
effectiveness calculator part of the model to determine the cost per QALY. Results: 
978 patients starting GA were enrolled (F: 755, M: 223), with an average age of 30.0 
years at entry. 898 BCMS patients were included as comparators. GA patients had 
a mean follow-up of 5.23 years (SD 1.33). The Markov model showed 30.3% slower 
EDSS progression for the GA cohort than predicted for untreated controls (progres-
sion ratio: 69.7%). Utility ratios were consistent with cost-effectiveness (ratio: 44.2%) 
for GA. Cost per QALY for GA was well below the target of £36,000. ConClusions: 
utilization and costs in individuals with probable DMD. Methods: We identified 
males aged 5-25 with at least one claim for hereditary progressive muscular dys-
trophy between 11/01/2011 and 10/31/2013 (date of first claim = index) from a US 
administrative claims database. Patients were required to be continuously enrolled 
with pharmacy benefits for 12 months after index date. Cardiac drugs, gastroin-
testinal drugs, and adrenals (including steroids) were evaluated in the 12 months 
after index. Number of inpatient and ER admissions, number of non-ER outpatient 
claims and prescriptions, as well as healthcare costs (overall and DMD-specific) 
were evaluated in the 12 months after index. Results: A total of 1,773 males with 
probable DMD were identified (mean age 14.5). We observed 368 (31%) patients on 
adrenals, 356 (30%) on cardiac drugs, and 124 (10%) with gastrointestinal drug use 
during follow-up. In the year after index, 16% had at least one inpatient admission 
(13% DMD-specific admissions), and 29% had at least one ER admission (13% DMD-
specific). The average number of outpatient claims was 79.8 (33.3 DMD-specific), and 
average number of prescriptions was 17.8. Mean annual costs were $34,381 ($17,581 
DMD-specific). ConClusions: Healthcare utilization and costs were substantial, 
and are likely to be underestimated due to inclusion of milder non-DMD forms of 
muscular dystrophy in the present study. Although DMD is a rare disease, the health 
burden and societal costs are considerable. New therapies to address the underlying 
disease are urgently needed.
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objeCtives: Understanding the health care costs associated with Multiple sclerosis 
(MS) in the geriatric population is not well studied. The objective of this study is 
to assess the health care costs associated with geriatric patients diagnosed with 
MS and taking disease modifying therapies (DMTs) in the US. Methods: A large 
US administrative retrospective claims database was used to identify patients 
diagnosed with MS and were prescribed DMTs between January 2010 to December 
2012 were included in the study. All patients were ≥ 65 years of age and continu-
ously enrolled in the same health plan for at least a year. Descriptive statistics and 
chi-square tests were performed on the data and statistical significance level was 
set a priori at 0.05. Results: There were a total of 88,921 patients that met the 
study inclusion criteria. Majority (66.9%) of the patients was taking subcutaneous 
injections (SC), 31.2% were taking IV/IM (IVM)and 1.9% was taking oral (OR) DMTs 
(p< 0.001). Patients on average were charged $4227.9± 2354.2 with a significant differ-
ence (p< 0.001) between the three drug groups (OR $5087 vs SC $4225 vs IVM $4188). 
However, the mean allowed amount by the health plan was $3692.5 ± 1915.5 and 
the actual paid amount was $3587.1 ± 1921.5 with a significant difference between 
the groups (p< 0.001). On average, patient’s deductible was $17.9 ± 207.8 and patient 
co-payment was $83.0 ± 304.3 with a difference between the groups (p< 0.001). For 
patients whose prescription was on their health plans formulary were charged lower 
($4187 vs $4246, p< 0.05) and paid lower co-payment ($78 vs $97, p< 0.001) than who 
were not. There was a significant variation in the cost of the treatments in different 
regions in the USA (p< 0.001). ConClusions: The overall costs for oral DMTs were 
higher than SC and IVM DMTs.
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objeCtives: There are currently several pharmaceutical options for multiple scle-
rosis (MS), some introduced recently and some more coming in the future. They are 
characterized by different modes of action, schemes of administration and, ulti-
mately, costs. MS resources management is thus complex and rely on proper interac-
tion between stakeholders – hospital pharmacists, MS department heads, hospital 
top management, local health representatives, heads of regional pharmaceutical 
policy. This is particularly true in Italy, a federal and delocalised setting comprising 
local, provincial, regional, and national decision makers. The aim of this work was 
to design a tool to explore the financial implications and ultimately align decision 
makers. Informed choices might save resources and support the adoption of inno-
vative treatments, thus contributing to overall sustainability and equity in patient 
access. Methods: We developed a dynamic user-friendly tool in Microsoft Excel® 
with VBA® macros. The flow of the analysis is stepwise and comprises, on top of 
adherence, variables usually excluded from standard budget impact such as intra- 
and inter-class switches, potential wash out period, as well as drop-out rates. All 
variables can be modified or excluded by users since default values can be restored 
at any time. The tool is open and can accommodate future treatments. Results: 
The tool assesses the financial impact of alternative choices in a comprehensive 
manner since results can be displayed with the desired level of detail – cumulative 
or annual, overall or by treatment line and/or cost item. ConClusions: This is an 
example of how to match the required level of information to specific end-users, 
encouraging both discussion and decision making in the best interest of patients. 
This is a prerequisite in multifaceted realities like Italy but it could assist in many 
other settings where stakeholders need to align to each other in order to forecasts 
accurately budget allocation.
PND96
humaNIstIc aND ecoNomIc burDeN of focal Drug-refractory 
ePIlePsy IN euroPe
Vrouchou P1, Risi A2, Annoni E3, Alvarez G4, Grovale N2
1Medtronic Europe, Tolochenaz, Switzerland, 2Medtronic Europe, Rome, Italy, 3Medtronic 
International Trading Sàrl, Tolochenaz, Switzerland, 4Medtronic USA, Louisville, CO, USA
